Disease-specific outcomes after chimeric antigen receptor T-cell therapy

Area of Science:

• Immunotherapy
• Hematology
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has revolutionized B-cell malignancy treatment.
• However, clinical trial data suggest variable efficacy and toxicity across different B-cell malignancies.

Purpose of the Study:

• To compare the efficacy and safety of CD19 CAR T-cells in patients with B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

Main Methods:

• Retrospective analysis of clinical trial data for patients with B-cell malignancies treated with the same CD19 CAR T-cell product.
• Comparison of primary resistance rates and acute toxicities (cytokine release syndrome, ICANS) across different indications.

Main Results:

• Follicular lymphoma (FL), mantle cell lymphoma (MCL), and B-cell acute lymphoblastic leukemia (B-ALL) demonstrated lower primary resistance rates compared to diffuse large B-cell lymphoma (DLBCL).
• Acute toxicities, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), were less severe in FL than in B-ALL, DLBCL, and MCL.

Conclusions:

• Disease-specific biology influences CAR T-cell therapy outcomes.
• Tailoring CD19 CAR T-cell strategies based on the specific B-cell malignancy may optimize treatment efficacy and safety.